BULARREKO MINBIZIA
![Foto de BULARREKO MINBIZIA](/img/grupo.png)
![Foto de Novartis (Sweden)](/img/noimage_org.png)
Novartis (Sweden)
Täby, SueciaNovartis (Sweden)-ko ikertzaileekin lankidetzan egindako argitalpenak (3)
2018
-
Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy
Breast Cancer Research and Treatment, Vol. 168, Núm. 2, pp. 357-364
2014
-
Phase lb study of buparlisib plus trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on trastuzumab-based therapy
Clinical Cancer Research, Vol. 20, Núm. 7, pp. 1935-1945
2007
-
Molecular response to aromatase inhibitor treatment in primary breast cancer
Breast Cancer Research, Vol. 9, Núm. 3